Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

Patients with diabetes or obesity receiving GLP-1 RAs are unlikely to experience an increase in the already low rates of ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Continuing GLP-1 RA use through surgery increases risk for surgical complications including aspiration and conversion to intubation ...

There’s no question about the popularity of GLP-1 weight loss drugs like Ozempic and Wegovy, but some doctors are worried the drugs are not intended for everyone and may be used by some patients ...

About 150 clients have adopted CVS Weight Management since it rolled out in 2023, and most are implementing it in conjunction with GLP-1 coverage. The company declined to specify the number of ...

While Lilly's success with GLP-1 drugs is certainly impressive, I have my eyes on another area of the company this year. Let's dig into what Lilly's business looks like beyond weight loss ...

CHICAGO, IL—The pool of patients who could potentially benefit from a glucagon-like peptide 1 (GLP-1) receptor agonist has expanded, thanks to new data showing that people with diabetes and ...

LINCOLN, Neb. (KOLN) - Popular GLP-1 drugs have been gaining traction across the United States as a means for weight loss. The drug has been approved to help treat type-2 diabetes, but a new study ...

You’d never guess it, but this is the latest exercise craze in action: Call it the GLP-1 workout. GLP-1 drugs such as semaglutide and tirzepatide have helped millions of people combat Type 2 ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...